Recruiting

Genetic Testing

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT01772771

Conditions

Glioma

Hematopoietic and Lymphoid Cell Neoplasm

Malignant Solid Neoplasm

Melanoma

Sarcoma

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Genetic Testing

Medical Chart Review

Study Details

Brief summary:

This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson. This may help doctors use testing information on tumors to identify clinical trials that may be most relevant to patients. Researchers may also use the information learned from this study to develop a database of the different kinds of mutations in cancer-related genes.

Conditions

Glioma

Hematopoietic and Lymphoid Cell Neoplasm

Malignant Solid Neoplasm

Melanoma

Sarcoma

Study ID

NCT01772771

Start date

Mar 1, 2012

Status verified date

Aug, 2026

Completion date

Mar 1, 2033

Anticipated

Primary completion date

Mar 1, 2032

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients must have histologically, radiographic, or cytologically documented cancer, suspected glioma, sarcoma, melanoma or hematologic cancer. Patients with benign tumors may also be consented at the discretion of the attending physician if molecular profiling is felt to have potential clinical implications.
  • Patients must have the ability to understand and the willingness to sign a written informed consent document
  • Patients may be consented without confirming the amount and quality of archival diagnostic or residual tissue available. However, research testing will only be performed on patients who have sufficient archived diagnostic tissue or residual tissue banked in one of the authorized tissue banks at MD Anderson available to proceed with testing. The extent of testing may be modified based on amount of tissue available. If any new tissue acquisition including a biopsy and/or surgical resection etc. is being ordered for clinical care or another research study, or an operation is being performed testing can be ordered on that sample
  • Circulating cell-free deoxyribonucleic acid (cfDNA) Cohort: Circulating cell-free DNA next generation sequencing (NGS) testing will be performed with the Clinical Laboratory Improvement Act (CLIA)-certified Guardant360 panel (or equivalent) for select patients. This particular cohort of research collaboration will be supported by Guardant Health, Inc. at no charge to MD Anderson. Patients who are being considered for enrollment into clinical trials in the next 2 lines of therapy may be enrolled. Selected patients may have cfDNA, circulating RNA /exosome/circulating tumor cell testing approaches performed on alternate platforms (eg Foundation ACT)

Study Design

Enrollment

12000 participants

Anticipated

Interventions and Outcome Measures

Arms

Ancillary-correlative (biospecimen collection, chart review)

Patients' previously collected tissue samples are analyzed. Patients may also undergo collection of blood, saliva or buccal samples for analysis. Patients' medical records are reviewed.

Interventions

Biospecimen Collection

Undergo collection of blood, saliva/buccal swab samples

Genetic Testing

Correlative studies

Medical Chart Review

Review of medical records

Primary outcome measure

  • Frequency of mutations and co-mutations [ Time Frame: 20 years ]
  • Distributions of mutations (including on gene expressions) [ Time Frame: 20 years ]
  • Database of somatic mutations and clinical characteristics [ Time Frame: 20 years ]

Central Contacts and Locations

Central contacts

Funda Meric-Bernstam, MD

713-792-6940fmeric@mdanderson.org

Locations

M D Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Funda Meric-Bernstam

713-792-6940

Principal Investigator:

Funda Meric-Bernstam

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Aug 21, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-08-21.